Surface Oncology Presents Preclinical Data Further Supporting Anti-Tumor Mechanism of CD73 and CD39 Programs at Brisbane Immunotherapy 2019


You May Also Like

Argos Announces One-for-Twenty Reverse Stock Split

DURHAM, N.C., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology ...

Adamis Pharmaceuticals Announces Agreement to Acquire US Compounding

SAN DIEGO, March 29, 2016 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Company” or ...